에 대한 최신 뉴스 Masimo (NASDAQ:MASI) 주식

MASIMO CORP

Masimo

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Equities

Large Cap

News

Movers

Trading Ideas

ERIE

FICO

LINE

MASI

NTNX

XPEV

지난주에 성과가 가장 좋았던 12개 대형주는 다음과 같다. 헤이코 샤오펑 리오토 리니지 이리 인뎀니티로이즈 뱅킹 유넘 페어 아이작 마시모 스미스 앤 네퓨 앤하이저부시 인베브 뉴타닉스

샤오펑·리오토·뉴타닉스 등 지난주 급등한 대형주 12종목 (2월 24일~28일)

Deal Dispatch

Asset Sales

Restaurants

DBRG

INRE

파산 블록 TGI 프라이데이스가 텍사스에서 챕터 11 파산 신청을 하며 재정적 구제를 위한 &#34;마지막 선택&#34;을 했다. 애피타이저, 윙 요리 및 칵테일로 유명한 이 레스토랑 체인은 재정 구조를 재편성하고 &#34;미래를 위한 전략적 대안 탐색&#34;을 시도하는 동안 39개의 회사 소유 매장을 계속 운영할 계획이다.

딜 디스패치: TGI 프라이데이스가 파산, BHP가 발언을 철회 등 더 많은 M&amp;A 뉴스

Why It Matters

AAPL

SSNLF

지난주는 애플(NASDAQ:AAPL)에게 롤러코스터와 같은 한 주였다. 미국의 조사로 인해 아이폰 칩 생산이 위협받기도 했고, 아이폰의 새로운 판매 기록이 세워지기도 했다. 이러한 발전들 가운데, 애플은 또한 특허 분쟁에 휘말렸고 주요 스트리밍 서비스들이 애플의 앱 스토어에서 이탈하는 것을 목격했다. 지난주에 발생한 주요 사건들을 요약하면 다음과 같다.

주간 주요 애플 뉴스: 기록적인 아이폰 판매부터 법률 및 규제 문제까지

Masimo Corp

Masivo Silver Corp

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 4.49% on an annualized basis producing an average annual return of 15.54%. Currently, Masimo has a market capitalization of $9.02 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 10 years ago, it would be worth $425.41 today based on a price of $167.01 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749736814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Masimo Stock In The Last 10 Years

EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.masimo.com&amp;esheet=54271413&amp;newsitemid=20250610391732&amp;lan=en-US&amp;anchor=Masimo&amp;index=1&amp;md5=6d262ad9f7b2d2ff51a19ad3b18cb9e8">Masimo</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine&#xAE; Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation anesthetic (sevoflurane) needed to maintain anesthesia in pediatric patients, reducing their exposure to the drug. In turn, the patients experienced a significantly lower rate of pediatric anesthesia emergence delirium, or PAED, which commonly manifests in confusion, agitation, or hallucinations experienced during recovery. When compared with standard practice, children monitored with SedLine also regained consciousness faster and could be safely discharged to the post-anesthesia care unit, or PACU, sooner – time savings that, the researchers noted, may represent additional cost savings. In sum, the researchers found that Masimo SedLine helped to make pediatric anesthesia safer, more efficient, and more cost effective.

Masimo Publishes Findings Of Randomized Clinical Trial In JAMA Pediatrics; Study Shows Ability Of EEG-Guided Anesthesia, Using Masimo Sedline Brain Function Monitoring, To Improve Anesthesia Administration In Children Undergoing Surgery

Biotech

General

Masimo Announces Findings In Trial Published In JAMA Pediatrics  Showing EEG-Guided Anesthesia Using Masimo Technology Reduced Pediatric Anesthesia Emergence Delirium, Time To Emergence And Discharge And Cost Of Care

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 2.29% on an annualized basis producing an average annual return of 14.41%. Currently, Masimo has a market capitalization of $8.92 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 15 years ago, it would be worth $779.18 today based on a price of $165.03 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748902514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Masimo 15 Years Ago Would Be Worth Today

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 17.24% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 8.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748448024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 5.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Masimo?

Guidance

Masimo To Re-Affirm Updated FY25 Financial Outlook

Raymond James analyst Jayson Bedford maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Outperform and lowers the price target from $204 to $185.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Masimo, Lowers Price Target to $185

WIIM

Masimo shares are trading lower. The company reported Q1 financial results and announced the sale of its consumer audio business for $350 million.

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 1.69% on an annualized basis producing an average annual return of 12.79%. Currently, Masimo has a market capitalization of $8.01 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 15 years ago, it would be worth $6,055.94 today based on a price of $148.31 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746629114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Piper Sandler analyst Jason Bednar reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and lowers the price target from $215 to $200.

Reiteration

Piper Sandler Reiterates Overweight on Masimo, Lowers Price Target to $200

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and lowers the price target from $205 to $190.

Wells Fargo Maintains Overweight on Masimo, Lowers Price Target to $190

Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), a leading global medical innovator, today announced that it has entered into a definitive agreement to sell its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., for an aggregate purchase price of $350 million in cash, subject to certain adjustments. The sale follows the previously announced review of Masimo's consumer audio business and will support the Company's strategic focus on driving innovation in its core professional healthcare segment. The transaction is expected to close by the end of 2025, subject to receiving necessary regulatory approvals.

Masimo Agrees To Sell Sound United Consumer Audio Business To HARMAN International For Aggregate Purchase Price Of $350M In Cash

2025 Outlook For Continuing Operations(4):
<ul>
<li>Non-GAAP revenue of $1,500 to $1,530 million, increasing 8% to 11% on a constant currency basis(3);</li>
</ul>
Excluding the impact of new tariffs (for comparison purposes only to prior guidance, which excluded new tariffs):
<ul>
<li>Non-GAAP operating profit of $420 to $436 million;</li>
<li>Non-GAAP operating margin of 28.0% to 28.5%; and</li>
<li>Non-GAAP earnings per diluted share of $5.30 to $5.60.</li>
</ul>
Updated guidance now includes the impact of new tariffs before any mitigation:
<ul>
<li>Non-GAAP operating profit of $383 to $403 million;</li>
<li>Non-GAAP operating margin of 25.5% to 26.4%; and</li>
<li>Non-GAAP earnings per diluted share of $4.80 to $5.15.</li>
</ul>
We have developed a number of mitigation plans and will continue to reassess and modify our plans as the situation merits. These plans include adjusting our product sourcing and operations to mitigate some of the impact, which is dependent on different tariff scenarios.
________________
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">The financial information reflects the continuing operations of Masimo's healthcare business.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1">The financial information reflects the Sound United business which is being classified as "held-for-sale" and reported in discontinued operations.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(3)</td>
<td colspan="1" rowspan="1">Represents a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is included in this earnings release.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(4)</td>
<td colspan="1" rowspan="1">Represents updated guidance provided May 6, 2025. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See "Forward-Looking Non-GAAP Financial Measures" within this earnings release, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. Guidance does not include any use of proceeds from a sale of Sound United and/or any potential benefits from new tax policies. Guidance includes the financial impact of one additional calendar week, which occurs every five or six years based on Masimo's 4-4-5 fiscal calendar. Guidance also includes the estimated financial impact of new tariffs (in place as of May 1, 2025), before any mitigation. The implementation of tariffs remains a dynamic and uncertain situation that could cause our actual results to be materially different from our projections and forecasts.</td>
</tr>
</tbody>
</table>
</figure>

Masimo Raises FY2025 Adj EPS Guidance from $5.10-$5.40 to $5.30-$5.60 vs $5.25 Est; Sees Sales $1.500B-$1.530B vs $1.52B Est

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $1.21 by 12.4 percent. This is a 106.06 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $371.00 million which beat the analyst consensus estimate of $367.54 million by 0.94 percent. This is a 24.72 percent decrease over sales of $492.80 million the same period last year.

Earnings

Earnings Beats

Masimo Q1 Adj. EPS $1.36 Beats $1.21 Estimate, Sales $371.00M Beat $367.54M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Masimo to report an earnings per share (EPS) of $1.21.
The announcement from Masimo is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.38, which was followed by a 12.35% increase in the share price the next day.
Here's a look at Masimo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.42</td>
<td>0.84</td>
<td>0.76</td>
<td>0.69</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.80</td>
<td>0.98</td>
<td>0.86</td>
<td>0.66</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>11.0%</td>
<td>11.0%</td>
<td>-12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746453826_0.png" alt="eps graph" />
<h3>Masimo Share Price Analysis</h3>
Shares of Masimo were trading at $166.42 as of May 02. Over the last 52-week period, shares are up 18.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Masimo</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Masimo.
Analysts have provided Masimo with 2 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $210.0, suggesting a potential 26.19% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Globus Medical, Penumbra and Teleflex, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Globus Medical, with an average 1-year price target of $90.4, suggesting a potential 45.68% downside.</li>
<li>Analysts currently favor an Buy trajectory for Penumbra, with an average 1-year price target of $317.0, suggesting a potential 90.48% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Teleflex, with an average 1-year price target of $148.5, suggesting a potential 10.77% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Globus Medical, Penumbra and Teleflex, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masimo</td>
<td>Outperform</td>
<td>9.44%</td>
<td>$244.70M</td>
<td>-27.80%</td>
</tr>
<tr>
<td>Globus Medical</td>
<td>Neutral</td>
<td>6.61%</td>
<td>$393.86M</td>
<td>0.64%</td>
</tr>
<tr>
<td>Penumbra</td>
<td>Buy</td>
<td>16.32%</td>
<td>$215.88M</td>
<td>3.32%</td>
</tr>
<tr>
<td>Teleflex</td>
<td>Neutral</td>
<td>-5.04%</td>
<td>$389.44M</td>
<td>2.27%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Masimo ranks highest in Revenue Growth among its peers. It has the lowest Gross Profit margin. Masimo's Return on Equity is negative, indicating lower profitability compared to its peers. Overall, Masimo is positioned differently across the metrics, with strengths in revenue growth but weaknesses in gross profit and return on equity.
<h3>All You Need to Know About Masimo</h3>
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Breaking Down Masimo's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Masimo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.44% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -58.2%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Masimo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -27.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Masimo's debt-to-equity ratio is below the industry average at 0.8, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MASI/earnings">To track all earnings releases for Masimo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Masimo's Earnings: A Preview

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has fallen 3.59% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 7.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745935223_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 4.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 3.14% on an annualized basis producing an average annual return of 13.67%. Currently, Masimo has a market capitalization of $8.45 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 15 years ago, it would be worth $6,943.24 today based on a price of $156.35 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745421313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today

Needham analyst Mike Matson reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) from Hold to Hold.

Needham Reiterates Hold on Masimoto Hold

Press Releases

Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference

Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6

Masimo Reports First Quarter 2025 Results

Masimo to Sell Consumer Audio Business to HARMAN International

Masimo to Present in the BofA Securities 2025 Health Care Conference

Legal

MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties

Masimo to Present in the Jefferies Global Healthcare Conference

New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Raymond James

Piper Sandler

Wells Fargo

Stifel

BTIG

지난주에 성과가 가장 좋았던 12개 대형주는 다음과 같다.
<ol>
<li>헤이코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>): 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/43990234" target="_blank" rel="noreferrer noopener">1분기 재무 실적</a>을 발표한 후 17.31% 상승했다.</li>
<li>샤오펑 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>): 에라자야 액티브 라이프스타일(Erajaya Active Lifestyle)이 <a href="https://www.benzinga.com/topic/electric-vehicle" target="_blank" rel="noreferrer noopener">인도네시아에서 샤오펑을 공식 출시</a>했다고 발표한 후 16.79% 급등했다.</li>
<li>리오토 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>): 회사가 첫 전기 SUV를 발표한 후 11.91% 상승했다. JP모건 애널리스트 닉 라이(Nick Lai)는 중립에서 비중확대 등급으로 상향 조정하고 목표주가를 <a href="https://www.benzinga.com/quote/li/analyst-ratings" target="_blank" rel="noreferrer noopener">22달러에서 40달러로 상향 조정</a>했다.</li>
<li>리니지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>): 회사가 <a href="https://www.benzinga.com//node/43967512" target="_blank" rel="noreferrer noopener">4분기 실적</a>을 발표한 후 11.82% 상승했다.</li>
<li>이리 인뎀니티 컴퍼니 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): 회사가 <a href="https://www.benzinga.com//node/44025334" target="_blank" rel="noreferrer noopener">4분기 EPS가 예상치를 상회</a>했다고 발표한 후 11.63% 상승했다.</li>
<li>로이즈 뱅킹 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYG#NYSE">LYG</a>): 11.28% 상승했다.</li>
<li>유넘 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>): 회사가 포티튜드 리(Fortitude Re)와 34억 달러 규모의 장기 요양 재보험 거래를 발표한 후 11.11% 상승했다.</li>
<li>페어 아이작 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>): RBC 캐피털 애널리스트 아시시 사바드라(Ashish Sabadra)가 주식을 섹터수익률에서 시장수익률 상회로 상향 조정하고 <a href="https://www.benzinga.com/quote/fico/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 2,040달러에서 2,170달러로 상향 조정</a>한 후 11.09% 상승했다.</li>
<li>마시모 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>): 회사가 <a href="https://www.benzinga.com//node/43956552" target="_blank" rel="noreferrer noopener">예상보다 좋은 실적</a>을 발표한 후 11.07% 상승했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/masi/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예상치</a>를 수정했다.</li>
<li>스미스 앤 네퓨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>): 회사가 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">2024회계연도 재무 실적</a>을 발표한 후 10.83% 상승했다.</li>
<li>앤하이저부시 인베브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>): 회사가 <a href="https://www.benzinga.com//node/43973849" target="_blank" rel="noreferrer noopener">4분기 실적과 매출이 예상보다 좋게 나왔다</a>고 발표한 후 10.79% 상승했다.</li>
<li>뉴타닉스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>): 회사가 <a href="https://www.benzinga.com//node/44007219" target="_blank" rel="noreferrer noopener">2분기 실적</a>을 발표한 후 10.25% 상승했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/ntnx/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예상치를 수정했다.</a></li>
</ol>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h3 class="wp-block-heading">파산 블록</h3>
TGI 프라이데이스가 텍사스에서 챕터 11 파산 신청을 하며 재정적 구제를 위한 &#8220;마지막 선택&#8221;을 했다. 애피타이저, 윙 요리 및 칵테일로 유명한 이 레스토랑 체인은 재정 구조를 재편성하고 <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">&#8220;미래를 위한 전략적 대안 탐색&#8221;</a>을 시도하는 동안 39개의 회사 소유 매장을 계속 운영할 계획이다.
56개의 미국 프랜차이즈와 40개의 해외 매장은 독립적으로 운영되며 영향을 받지 않는다.
이 체인의 재정적 문제는 팬데믹의 여파와 일부 불안정한 자본 구조 선택 때문이라고 로히트 마노차(Rohit Manocha) 집행 회장이 밝혔다. TGI 프라이데이스는 사모펀드 트라이아티산 캐피털 파트너스(TriArtisan Capital Partners)가 소유하고 있다.
<h3 class="wp-block-heading">신규 블록</h3>
인랜드 리얼 에스테이트 인컴 트러스트(OTC:<a class="ticker" href="https://www.benzinga.com/stock/INRE#OTC">INRE</a>)가 BMO 캐피털 마켓을 고용하여 잠재적 매각 과정을 조언받고 있다. 현재 3억 9,500만 달러의 시가총액을 보유한 이 부동산 신탁은 금요일 주가가 1.35% 하락하여 10.95달러에 마감되었다.
BT(LSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/bt" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BT">BT</a>)는 라디안즈(Radianz)라는 금융 서비스 부문의 매수자를 찾기 위해 씨티그룹을 고용했다고 <a href="https://www.ft.com/content/6fe5e337-18dc-4a32-8e6e-e759a977b490">파이낸셜 타임스</a>가 보도했다.
디지털브릿지 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>)는 브라질의 스칼라 데이터 센터(Scala Data Centers)를 20억 달러에 매각할 계획을 세우고 있다고 <a href="https://www.bloomberg.com/news/articles/2024-10-24/digitalbridge-is-said-to-explore-a-sale-of-scala-data-centers">블룸버그</a>가 보도했다.
코노코필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)는 <a href="https://www.reuters.com/business/energy/conocophillips-explores-sale-permian-shale-assets-worth-over-1-billion-sources-2024-10-30/">로이터</a> 보도에 따르면, 퍼미안 분지의 셰일 자산을 경매에 부치고 있으며, 예상 수입은 10억 달러 이상이다.
참고: <a href="https://www.benzinga.com/news/24/11/41698607/kamala-harris-ready-if-trump-decides-to-falsely-declare-victory-we-are-prepared-to-respond">해리스를 준비시키다: 트럼프가 승리를 거짓으로 선언하기로 결정하면 우리는 대응할 준비가 되어 있다</a>
<h3 class="wp-block-heading">블록 업데이트</h3>
BHP 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)이 실패한 앵글로 아메리칸(Anglo American Plc) 인수 건에서 &#8220;진전을 이뤘다&#8221;고 언급한 것에 대해 <a href="https://www.benzinga.com/news/large-cap/24/11/41684205/bhp-backtracks-its-comments-on-abandoning-anglo-american-deal">발언을 번복</a>했다. BHP의 회장인 켄 맥켄지(Ken MacKenzie)는 수요일 주주총회에서 이 발언을 했으며, 블룸버그가 이 개발을 최초로 <a href="https://www.bloomberg.com/news/articles/2024-10-30/bhp-retreats-from-comments-about-moving-on-from-anglo-bid?sref=TBDibEcD" target="_blank" rel="noopener">보도</a>했다.
텔레폰 앤드 데이터 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>)의 CFO인 비키 빌라크레즈(Vicki Villacrez)가 최근 실적 발표 전화 회의에서 진행 중인 매각 과정을 논의했다. 이 회사는 9월에 원넥 IT 솔루션즈(OneNeck IT Solutions)의 매각을 완료한 후 다른 자산 매각에 동의했다. 이 거래들은 올해 말에 마무리될 것으로 예상된다.
블랙스톤이 EQT(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)가 소유한 주간 천연가스 파이프라인의 소수 지분 인수에 대해 35억 달러를 고려하고 있다고 로이터가 보도했다.
지금 읽기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/ai-%EB%AC%BC%EA%B2%B0%EC%9D%84-%ED%83%80%EA%B3%A0-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%82%B0%EC%97%85%ED%8F%89%EA%B7%A0-%EC%A7%80%EC%88%98%EC%97%90/" target="_blank" rel="noopener">엔비디아, AI 바람을 타고 인텔을 다우존스 산업평균지수에서 25년 만에 교체하다</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

딜 디스패치: TGI 프라이데이스가 파산, BHP가 발언을 철회 등 더 많은 M&A 뉴스

지난주는 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)에게 롤러코스터와 같은 한 주였다. 미국의 조사로 인해 아이폰 칩 생산이 위협받기도 했고, 아이폰의 새로운 판매 기록이 세워지기도 했다. 이러한 발전들 가운데, 애플은 또한 특허 분쟁에 휘말렸고 주요 스트리밍 서비스들이 애플의 앱 스토어에서 이탈하는 것을 목격했다. 지난주에 발생한 주요 사건들을 요약하면 다음과 같다.
미국 조사가 애플의 아이폰 칩 생산을 위협
미국 상무부가 대만 반도체 제조 회사(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)에 대한 조사를 시작했다. 이는 제재 위반 가능성을 의심하는 것으로, TSMC가 화웨이 테크놀로지스(Huawei Technologies)에 칩을 공급하기 위해 중개 회사를 이용하여 제재를 위반했는지를 조사하고 있다. 이 조사는 애플의 아이폰과 맥용 칩 생산에 잠재적으로 차질을 빚을 수 있다.
<a href="https://www.benzinga.com/news/24/10/41415320/us-probe-into-potential-sanctions-breach-by-tsmc-threatens-apples-iphone-chips-production">전체 기사를 여기서 읽어보세요.</a>
디즈니와 훌루, 애플의 앱 스토어를 우회
월트 디즈니 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)는 고객들이 애의 앱 스토어를 통해 훌루와 디즈니+에 구독할 수 없도록 하여, 아이폰 제조사의 인앱 구매 수수료를 피했다. 이제 고객들은 모든 요금을 확인하고 직접 웹사이트에서 구독 신청을 하도록 안내받아, 애플이 인앱 구매 시 부과하는 15%에서 30%의 수수료를 우회할 수 있다.
<a href="https://www.benzinga.com/general/entertainment/24/10/41443702/disney-and-hulu-stream-away-from-apples-30-toll-bridge-what-it-means-for-the-iphone-maker">전체 기사를 여기서 읽어보세요.</a>
참고: <a href="https://www.benzinga.com/top-stories/24/10/41529265/apple-hints-at-major-mac-updates-with-rumored-m4-powered-lineup?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">애플, M4 기반 라인업으로 주요 맥 업데이트 암시</a>
애플 인텔리전스에 대한 회의론
애플의 기대되는 새로운 인공지능 시스템인 애플 인텔리전스(Apple Intelligence)는 회의론에 직면했다. 블룸버그 칼럼니스트인 마크 구르만(Mark Gurman)은 이 시스템이 높은 기대치를 충족하지 못할 수도 있으며, 새로운 인공지능(AI) 기능이 다음 주에 공개될 때 소비자들이 실망하거나 혼란스러워할 수 있다고 의구심을 제기했다.
<a href="https://www.benzinga.com/news/24/10/41420086/apple-intelligences-meh-moment-ahead-analyst-predicts-5-months-of-build-up-could-lead-to-a-thats-it">전체 기사를 여기서 읽어보세요.</a>
3분기 아이폰 판매 기록 갱신
애플은 2024년 3분기 동안 아이폰에 대한 새로운 판매 기록을 세웠다. 이는 전 세계 스마트폰 시장의 더 넓은 회복과 동시에 발생한 일이다. 캐널라이스(Canalys)에 따르면, 애플의 아이폰 판매량은 삼성전자(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>)에게 아슬아슬하게 뒤쳐졌으며, 두 기술 거인이 모두 18%의 시장 점유율을 차지했다.
<a href="https://www.benzinga.com/markets/equities/24/10/41328252/apples-iphone-16-powers-record-sales-in-q3-just-behind-samsung-in-global-market-share-battle">전체 기사를 여기서 읽어보세요.</a>
애플, 마시모와의 특허 분쟁에서 승리
델라웨어 배심원이 애플의 손을 들어주는 특허 침해 사건에서 마시모(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>)에게 상징적인 250달러의 배상을 판결했다. 배심원은 마시모가 시장에 더 이상 없는 구형 스마트워치 모델과 관련된 애플의 건강 기술 특허를 침해했다고 판단했다.
<a href="https://www.benzinga.com/news/24/10/41562593/apple-secures-victory-in-masimo-patent-dispute-with-token-damages-of-250">전체 기사를 여기서 읽어보세요.</a>
다음 읽기:
<a href="https://kr.benzinga.com/news/global/%ED%91%B8%ED%8B%B4%EC%9D%B4-%EC%9D%BC%EB%A1%A0-%EB%A8%B8%EC%8A%A4%ED%81%AC%EC%97%90%EA%B2%8C-%EC%8B%9C%EC%A7%84%ED%95%91%EC%9D%84-%EB%B0%B0%EB%A0%A4%ED%95%B4-%EB%8C%80%EB%A7%8C-%EB%82%B4-%EC%8A%A4/" target="_blank" rel="noopener">러시아 대통령, 일론 머스크에게 대만 문제로 스타링크 서비스 제한 요청</a>
사진 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Masimo

뉴스

에 대한 최신 뉴스 Masimo (NASDAQ:MASI) 주식

일요일, 3월 02, 2025

토요일, 11월 02, 2024

일요일, 10월 27, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌